The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Catherine, Kandahari, Adrese Michael, Ujjani, Chaitra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910100/
https://www.ncbi.nlm.nih.gov/pubmed/31849558
http://dx.doi.org/10.2147/BLCTT.S231821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910100/
https://www.ncbi.nlm.nih.gov/pubmed/31849558
http://dx.doi.org/10.2147/BLCTT.S231821

Ejemplares similares